Deep Science Ventures is creating a future in which both humans and the planet can thrive. We use our unique venture creation process to create, spin-out and invest into science companies, combining available scientific knowledge and founder-type scientists into high-impact ventures. We operate in 4 sectors: Pharmaceuticals, Climate, Agriculture and Computation, tackling the challenges defining those areas by taking a first principles approach and partnering with leading institutions.
Driven by mutual conviction in the huge unmet medical need in fibrotic diseases, DSV has partnered with General Inception to accelerate the development of novel therapeutics, jointly building a new venture solely dedicated to anti-fibrotic therapies. To maximise impact and exploit synergies across both organisations, we are forging a new venture creation model which combines DSV’s innovative first-principles venture creation methodology with General Inception’s deep domain expertise, network and portfolio - leveraging the best of both.
To learn more about the partnership, please see our Press Release, and to learn more about General Inception
We are looking for future Founders: entrepreneurially-minded individuals with deep technical and commercial domain expertise, who are eager to solve urgent unmet challenges through venture building. This role offers a unique opportunity to work at the forefront of fibrosis drug development, solving challenges in protein engineering and myeloid reprogramming to reverse disease.
You will join DSV’s venture creation programme as a Founder-in-Residence and work closely with the DSV and GI team to spin out the new company. During the programme you will refine, improve and complement existing scoping work on:
Preparation for investment decision committee will involve fulfilling any outstanding investment criteria, recruiting advisory and co-founding team members, and fundraising for additional expansion funds.
Assuming success at both respective Investment Committees, you will receive pre-seed investment from DSV and GI, and spinout the company in early Q4 2025. You and your co-founders will own the majority stake in the business and continue receiving support post-spinout.
Fibrosis underlies a staggering proportion of human diseases, accounting for 18% of all global deaths (35% including solid tumours), with increasing prevalence worldwide, and consistent market growth across almost all indications. Yet there are still only two FDA-approved anti-fibrotic drugs – marketed for lung fibrosis alone – neither of which are able to meaningfully halt disease, let alone reverse it.
The unmet medical need is therefore enormous. But competition in the development pipeline is increasingly fierce for liver and lung fibrosis, and many clinical approaches have historically proven to be intractable at reversing disease, teaching us valuable biological lessons that must be incorporated for the next generation of therapeutics. To reverse disease, we must directly or indirectly achieve multiple biological outcomes – manipulating pathogenic myofibroblasts, resolving pro-fibrotic inflammation, regenerating healthy epithelia & endothelia, degrading existing ECM deposits, and ideally neutralising (reactivity to) any upstream triggers. We believe we have identified approaches that may be able to address many if not all of these outcomes, by focussing on pro-resolution mechanisms and immune reprogramming.
Our ambition is to create impactful new medicines that have (i) transformative mono-therapeutic efficacy, (ii) applicability across multiple fibrotic diseases (beyond the lung), (iii) complementary yet distinct mechanism of action compared to standard-of-care medicines (to ensure combinability with future clinical regimens), and (iv) conveniently and/or infrequently administered (to ensure patient convenience and low burden on healthcare systems).
To this end, we want to pursue a multi-strategy portfolio of approaches that balance ambition, derisking, speed, and optionality, while maintaining focus on key biology areas where we can develop deep expertise and know-how. This will require a talented expert in protein engineering and/or myeloid reprogramming to join the Founding team.
We believe now is the time to turn this vision into a reality. Will you join us to lead the effort?
We are looking for an exceptional individual with the following:
Essential (must-have)
Preferred (nice-to-have)
By joining DSV, you’ll be joining a team of operators who have founded companies and led translation of science at some of the most respected universities, charities, funds and government agencies. 2/3 of the team have founded or led a company at C-suite and 65% have a PhD. Our team dedicate several hours every week to each Founder or founding team to provide tailored guidance, resources and feedback covering every aspect of what it takes to successfully launch a new venture from both the tech and commercial perspectives:
If an employer mentions a salary or salary range on their job, we display it as an "Employer Estimate". If a job has no salary data, Rise displays an estimate if available.
Lead Ingredion’s global Measurement Science strategy to accelerate innovation and growth as Director of Measurement Science based in Bridgewater, NJ.
Eurofins Scientific seeks a QC Microbiology Technician for 2nd shift environmental monitoring and sampling at their biopharmaceutical manufacturing site in Rensselaer, NY.
AbbVie is seeking a Scientist II to design and execute experiments that advance innovative pharmaceutical solutions in Barceloneta, Puerto Rico.
Experienced Architectural Engineers are sought to collaborate with AI teams remotely at RYZ Labs to help train advanced AI models in architectural-engineering expertise.
Contribute to biomedical engineering research at Emory University as an Assistant Academic Research Scientist, driving experimental design and data analysis.
Eurofins Scientific is looking for an Associate Formulations Scientist in Groton, CT to develop and evaluate innovative pharmaceutical formulations for preclinical and clinical study support.
Lead the Advanced Product Development team at Intuitive to create cutting-edge medical solutions addressing unmet clinical needs in minimally invasive care.
Lead a dynamic Process Sciences team at Eurofins to drive excellence in biologics manufacturing and laboratory operations.
Envalior is looking for an experienced Advanced Development Expert to spearhead automotive electronics innovation at their Troy office with global project responsibility.
Gridmatic is seeking a skilled Atmospheric Engineer to enhance weather modeling capabilities and contribute to energy forecasting innovations in a dynamic startup environment.
Avantor is looking for a Lab Support Specialist in Watertown, MA to provide key operational and technical support in chemistry laboratories, enabling scientists to focus on research.
Eurofins Scientific is seeking a detail-oriented Bioreactor Scientist in Kalamazoo, MI, to drive CHO cell culture processes and bioprocess optimization within their upstream development team.
Alcon seeks talented engineering graduates for a 3-year rotational R&D program fostering innovation in eye care technologies.
Subscribe to Rise newsletter